Mathew Maccumber, MD
Retina Specialist · Harvey, ILNPI 1649270224
Payments from drug & device makers
Across 657 payments — averaging $2647.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ocular Therapeutix, Inc.$1.1M
- Apellis Pharmaceuticals, Inc.$157K
- Boehringer Ingelheim$146K
- Regeneron Healthcare Solutions, Inc.$64K
- ANI Pharmaceuticals, Inc.$52K
- Regeneron$41K
- plus $163K from 19 others
Across 22 payments — averaging $2211.11 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$22K
- Alimera Sciences, Inc.$12K
- Ocular Therapeutix, Inc.$10K
- Novartis Pharma AG$4K
- Regeneron$2K
What the payments were for
- Consulting fees$129,64459%
- Speaking & faculty fees$59,58127%
- Travel & lodging$7,1353%
- Food & beverage$11,2145%
- Ownership interest$4,7722%
- Other$6,6523%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ocular Therapeutix, Inc. | 130 | $1,115,336 |
| Apellis Pharmaceuticals, Inc. | 72 | $157,313 |
| Boehringer Ingelheim | 32 | $146,285 |
| Regeneron Healthcare Solutions, Inc. | 79 | $63,912 |
| ANI Pharmaceuticals, Inc. | 9 | $52,348 |
| Regeneron | 111 | $41,058 |
| Astellas Pharma US Inc | 30 | $27,013 |
| Spark Therapeutics, Inc. | 15 | $25,105 |
| Novartis | 17 | $24,621 |
| Alimera Sciences, Inc. | 22 | $15,602 |
| Genentech USA, Inc. | 24 | $13,764 |
| Astellas Pharma Global Development | 5 | $12,850 |
| US Retina LLC | 14 | $12,824 |
| AbbVie(2 entities) | 20 | $11,505 |
| Bausch & Lomb Americas Inc. | 13 | $8,531 |
| Boehringer Ingelheim International GmbH | 32 | $3,666 |
| Thrombogenics, Inc. | 2 | $3,000 |
| Eyepoint US, Inc. | 5 | $2,124 |
| Coherus Oncology, Inc. | 4 | $1,405 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 13 | $426 |
| Harrow Eye, LLC | 4 | $251 |
| Alcon | 1 | $125 |
| Notal Vision, Inc. | 1 | $46 |
| Vyera Pharmaceuticals, LLC | 1 | $20 |
| Oyster Point Pharma, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,739,144 in reported general payments places this provider in the 95th percentile of 70 retina specialist providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 20 | $18,669 |
| ProlensaBromfenac Sodium | 29 | $10,022 |
| Bromfenac Sodium | 45 | $6,685 |
| Prednisolone Acetate | 115 | $5,318 |
| Difluprednate | 37 | $4,755 |
| Ketorolac Tromethamine | 92 | $2,082 |
| Cyclosporine | 11 | $1,995 |
| Brimonidine Tartrate | 26 | $1,418 |
| Travoprost | 11 | $1,114 |
| Latanoprost | 58 | $873 |
| Atropine Sulfate | 22 | $863 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 60 | $788 |
| ErythromycinErythromycin Base | 58 | $557 |
| Dorzolamide Hcl | 35 | $553 |
| Timolol Maleate | 38 | $427 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis | $11,505 | $18,66920 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa | $426 | $10,02229 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 70 retina specialist providers in Illinois.
Other retina specialist in Harvey
- Vivek ChaturvediHarvey$852K
- Joseph CivantosHarvey$645K
- Kourous RezaeiHarvey$126K
- Kirk PackoHarvey$96K
- David OrthHarvey$70K
- Timothy FloodHarvey$57K
- Serge DebustrosHarvey$34K
- Sohail HasanHarvey$30K
- Jack CohenHarvey$24K
- Zac RavageHarvey$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.